Yahoo
NYSE American - Delayed Quote USD

Cryo-Cell International, Inc. (CCEL)

4.8900 -0.0600 (-1.21%)
At close: 4:00:00 PM EST
Chart Range Bar
Loading chart for CCEL
  • Previous Close 4.9500
  • Open 4.7500
  • Bid 4.9400 x 10000
  • Ask 5.0000 x 30000
  • Day's Range 4.7500 - 4.9450
  • 52 Week Range 2.7200 - 5.4500
  • Volume 9,458
  • Avg. Volume 24,014
  • Market Cap (intraday) 39.426M
  • Beta (5Y Monthly) 0.55
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2400
  • Earnings Date (est.) --
  • Forward Dividend & Yield 0.60 (0.00%)
  • Ex-Dividend Date May 21, 2025
  • 1y Target Est --

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

www.cryo-cell.com

72

Full Time Employees

November 30

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CCEL
42.15%
S&P 500 (^GSPC)
7.76%

1-Year Return

CCEL
13.72%
S&P 500 (^GSPC)
9.77%

3-Year Return

CCEL
7.04%
S&P 500 (^GSPC)
68.96%

5-Year Return

CCEL
50.23%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 7.82M
Earnings 1.27M
Profit Margin 16.24%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-2M
0
2M
4M
6M
-40.0%
-20.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.25%

  • Return on Assets (ttm)

    0.19%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    31.13M

  • Net Income Avi to Common (ttm)

    -1.95M

  • Diluted EPS (ttm)

    -0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.23M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -66.21k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: